Your browser doesn't support javascript.
loading
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard, N; Galland-Girodet, S; Avrillon, V; Besse, B; Duruisseaux, M; Cadranel, J; Otto, J; Prevost, A; Roch, B; Bennouna, J; Bouledrak, K; Coudurier, M; Egenod, T; Lamy, R; Ricordel, C; Moro-Sibilot, D; Odier, L; Tillon-Strozyk, J; Zalcman, G; Missy, P; Westeel, V; Baldacci, S.
Affiliation
  • Girard N; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Université Versailles Saint Quentin, Paris Saclay Campus, Versailles, France. Electronic address: nicolas.girard2@curie.fr.
  • Galland-Girodet S; Service d'Oncologie - Radiothérapie, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
  • Avrillon V; Service d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.
  • Besse B; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; Paris-Saclay University, Orsay, France.
  • Duruisseaux M; Unité de Recherche Commune en Oncologie Thoracique (URCOT), Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France; Service de Pneumologie, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Ly
  • Cadranel J; Chest Department, AP-HP Hôpital Tenon and GRC#4 Theranoscan Sorbonne Université Paris, Paris, France.
  • Otto J; Oncologie, Centre Anticancer Antoine Lacassagne, Nice, France.
  • Prevost A; Institut Godinot, Reims, France.
  • Roch B; Unité d'Oncologie Thoracique, Département de Pneumologie, CHU Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier, U1194, Campus Val d'Aurelle, Montpellier, France; Université de Montpellier, Montpellier, France.
  • Bennouna J; Thoracic Oncology Unit, University Hospital of Nantes, Nantes, France.
  • Bouledrak K; Oncologie Médicale et Pneumologie, Hôpital Privé Jean Mermoz, Lyon, France.
  • Coudurier M; Pneumologie, Centre hospitalier Métropole Savoie, Chambery, France.
  • Egenod T; Thoracic Oncology Department, CHU Limoges - Hôpital Dupuytren, Limoges, France.
  • Lamy R; Oncologie, GHBS, Lorient, France.
  • Ricordel C; Department of Pulmonary Medicine, CHU Pontchaillou, Rennes, France.
  • Moro-Sibilot D; Thoracic Oncology, CHU de Grenoble, Hôpital Michallon, La Tronche, France.
  • Odier L; Pneumology, L'Hôpital Nord Ouest Villefranche-Sur-Saône, Gleize, France.
  • Tillon-Strozyk J; Clinique Pneumologique, Hôpital Charles Nicolle, Rouen, France.
  • Zalcman G; Department of Thoracic Oncology and CIC1425, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, Paris, France.
  • Missy P; French Cooperative Thoracic Intergroup, Paris, France.
  • Westeel V; Oncologie Thoracique et Allergologie Respiratoire, CHRU Besancon - Hôpital Jean Minjoz, Besançon, France.
  • Baldacci S; Lille University, CHU Lille, Thoracic Oncology Department, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, Lille, France.
ESMO Open ; 7(2): 100418, 2022 04.
Article in En | MEDLINE | ID: mdl-35227966
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Female / Humans / Male / Middle aged Language: En Journal: ESMO Open Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Female / Humans / Male / Middle aged Language: En Journal: ESMO Open Year: 2022 Document type: Article